Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.53 |
| ▸ | FPR2 | P25090 | 6/20 | 0.49 |
| ▸ | PROKR1 | Q8TCW9 | 6/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22350849 | 0.91 | HTR2C (0.50) | HTR2CHTR2BFPR2PROKR1SCN1A | |
| SCHEMBL14294081 | 0.87 | RORC (0.54) | HTR2CHTR2BFPR2PROKR1SYK | |
| SCHEMBL16695295 | 0.86 | KDM4E (0.50) | HTR2CHTR2BFPR2PROKR1RORC | |
| SCHEMBL10196595 | 0.84 | ACHE (0.52) | HTR2CHTR2BFPR2PROKR1SYK | |
| SCHEMBL5544941 | 0.84 | HTR2C (0.49) | HTR2CHTR2BSYKSCN1ASCN2A | |
| SCHEMBL5536788 | 0.84 | HTR2C (0.46) | HTR2CHTR2BSYKSCN1ASCN2A | |
| SCHEMBL13678433 | 0.83 | CSNK2A1 (0.55) | HTR2CHTR2BFPR2PROKR1SYK | |
| SCHEMBL12908030 | 0.83 | CSNK2A1 (0.59) | SYKRORCCSNK2A1 | |
| SCHEMBL3973906 | 0.83 | KDM4E (0.49) | HTR2CHTR2BFPR2PROKR1RORC | |
| SCHEMBL14578222 | 0.82 | CSNK2A1 (0.55) | HTR2CHTR2BFPR2PROKR1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | HTR2C 4096/4885HTR2B 4492/4885FPR2 1472/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | HTR2C 4577/4885HTR2B 4837/4885FPR2 1687/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | HTR2C 4599/4885HTR2B 4823/4885FPR2 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.